Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The study is an observer-blind, randomized, controlled prospective intervention study of Phase I. The primary objective is To evaluate the safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose.
Epistemonikos ID: f965b2f79094abed302c621bf3cbb93495dc8c45
First added on: Oct 06, 2021